MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Parkinson’s Disease, Cognition, Positive Symptoms and Medication Management

O. Kaczmarek, S. Baek, A. Sethi, A. Stolarczyk, B. Bumstead, M. Buhse, M. Zarif, B. Anand, M. Gudesblatt (Patchogue, USA)

Meeting: 2022 International Congress

Abstract Number: 873

Keywords: Psychosis

Category: Rating Scales

Objective: Explore the relationship between multi-domain cognitive testing and patient-reported psychiatric symptoms in PwPD to self-medication management capabilities.

Background: Parkinson’s disease (PD) is a complex neurodegenerative disorder characterized by varied degrees and combinations of cognitive, psychiatric and motor dysfunctions. Pharmacotherapy management of symptoms is the most common approach to treatment but medication regimens can be complicated, burdensome, and change as recognized disease impact evolves. “Psychiatric” symptoms may affect up to 50% of people with PD (PwPD) and may adversely impact the capacity for independent self-medication management. Accurate identification of the degree of such symptoms may enhance the provider’s ability to assess appropriate medication adherence and consider alternate solutions or regimens. Clinicians’ accurate recognition, appreciation and willingness to address these symptoms in PwPD might be problematic.

Method: Retrospective review of data collected through routine care of PwPD that were evaluated by multi-domain computerized cognitive testing and completed patient reported outcomes (PROs): Self-Efficacy for Managing Medications and Treatments Short Form 4a (MM) and Scale for the Assessment of Positive Symptoms (SAPS-PD). Cognitive domains assessed were: Memory, Executive Function, Visual Spatial, Information Processing, Verbal Function, Attention and a Global Cognitive Summary Score (GCS).

Results: 161 PwPD, 60% male, average age 73+/- 13 years. Significant relationships were identified by regression analysis (p<0.01) for the following: MM and SAPS-PD (r2 = 0.22), MM vs GCS (r2 = 0.39). 27% of PwPD reported low confidence in self-managing medications (37% of males and 21% of females).

Conclusion: Low confidence in medication self-management in PwPD is more common than appreciated. Self-management of medications decline with increased SAPS-PD symptom impairment and MM is also impacted by cognitive impairment (CI) measured by objective multi-domain cognitive assessment. SAPS-PD PRO and objective multidomain cognitive testing can enhance recognition for addressing issues related to impaired self-management of medication and cognitive impairment in PwPD. Increased adherence to prescribed medication schedules and addressing such unmet needs as insufficient medication management can aide in optimizing care plans.

GCS vs MM

SAPS-PD vs MM

To cite this abstract in AMA style:

O. Kaczmarek, S. Baek, A. Sethi, A. Stolarczyk, B. Bumstead, M. Buhse, M. Zarif, B. Anand, M. Gudesblatt. Parkinson’s Disease, Cognition, Positive Symptoms and Medication Management [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/parkinsons-disease-cognition-positive-symptoms-and-medication-management/. Accessed September 21, 2023.
  • Tweet
  • Email
  • Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/parkinsons-disease-cognition-positive-symptoms-and-medication-management/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Carpal Tunnel Syndrome in Patients with Tremor
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #23972 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • #22892 (not found)
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Insulin dependent diabetes and hand tremor
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley